Rohto Pharmaceutical Co.,Ltd.
RPHCF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 58.85 | 1.33 | 0.80 | 0.75 |
| FCF Yield | 3.84% | 3.57% | 0.03% | 0.03% |
| EV / EBITDA | 11.69 | 12.50 | 12.35 | 12.16 |
| Quality | ||||
| ROIC | 8.52% | 11.45% | 443.30% | 227.33% |
| Gross Margin | 56.68% | 58.07% | 0.43% | 0.47% |
| Cash Conversion Ratio | 0.87 | 0.82 | 1.17 | 1.29 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.95% | 10.70% | 9.65% | 385.47% |
| Free Cash Flow Growth | 4.04% | 15,914.55% | 20.94% | 48.94% |
| Safety | ||||
| Net Debt / EBITDA | -0.48 | -1.56 | -0.01 | 0.58 |
| Interest Coverage | 41.03 | 204.33 | 137.49 | 117.00 |
| Efficiency | ||||
| Inventory Turnover | 2.17 | 2.43 | 0.02 | 2.55 |
| Cash Conversion Cycle | 171.86 | 155.66 | 11,787.47 | -6,890.63 |